The NSCLC-PD-L1 low expression (1%-40%) had a trend towards increased odds of 18-month survival after diagnosis (AOR = 1.53, 95% CI 0.92-2.53) but without significant probability (p = 0.10). This evidence concerns the gene CD274 and non-small cell lung carcinoma.